Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)

References

• CarrellRWLomasDASidharSForemanRAlpha1-antitrypsin deficiency. A conformational diseaseChest19961102432478681634
   PubMed Web of Science ®Google Scholar
• LomasDAMahadevaRAlpha-1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapyJ Clin Invest20021101585159012464660
   PubMed Web of Science ®Google Scholar
• CasasFBlancoIMartínezMTIndications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease: an updateArch Bronconeumol20155118519225027067
   PubMed Web of Science ®Google Scholar
• MiravitllesMDirksenAFerrarottiIEuropean Respiratory Society statement: diagnosis and treatment of pulmonary disease in α-1-antitrypsin deficiencyEur Respir J2017505 pii:1700610
   Web of Science ®Google Scholar
• SeersholmNKok-JensenADirksenASurvival of patients with severe AATD with special reference to non-index casesThorax1994496956988066566
   PubMed Web of Science ®Google Scholar
• TanashHANilssonPMNilssonJAPituilainenEClinical course and prognosis of never smokers with severe AATD (PiZ)Thorax2008631091109518682522
   PubMed Web of Science ®Google Scholar
• Tirado-CondeGLaraBCasasFFactors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registryArch Bronconeumol20114749550321798656
   PubMed Web of Science ®Google Scholar
• MiravitllesMVidalRBarros-TizónJCUsefulness of a national registry of alpha-1 antitrypsin deficiency. The Spanish experienceRespir Med199892118111879926146
   PubMed Web of Science ®Google Scholar
• LaraBBlancoIMartínezMTSpanish registry of patients with alpha-1 antitrypsin deficiency: database evaluation and population analysisArch Bronconeumol201753131827323654
   PubMed Web of Science ®Google Scholar
• García-RíoFCalleMBurgosFSpanish Society of Pulmonology and Thoracic Surgery (SEPAR)Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)Arch Bronconeumol20134938840123726118
   PubMed Web of Science ®Google Scholar
• VidalRMiravitllesMA report on the Spanish registry of patients with alpha-1 antitrypsin deficiency. The alpha-1 antitrypsin deficiency study groupArch Bronconeumol1995312993027627428
   PubMedGoogle Scholar
• LaraBMiravitllesMSpanish registry of patients with alpha-1 antitrypsin deficiency; comparison of the characteristics of PiSZ and PiZZ individualsCOPD201512S1273125938288
   PubMedGoogle Scholar
• SeersholmNKok-JensenASurvival in relation to lung function and smoking cessation in patients with severe hederatary alpha 1-antritrypsin deficiencyAm J Respir Crit Care Med19951513693737842193
   PubMed Web of Science ®Google Scholar
• Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha 1 Antitrypsin Deficiency GroupAm J Respir Crit Care Med19981854449
   Google Scholar
• StockleyRAEdgarRGPillaiATurnerAMIndividualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?Int J Chron Obst Pulm Dis20161117451756
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med20113651184119221991892
   PubMed Web of Science ®Google Scholar
• CasanovaCde TorresJPAguirre-JaímeAThe progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohortAm J Respir Crit Care Med20111841015102121836135
   PubMed Web of Science ®Google Scholar
• KoskelaJKatajistoMKallioAKilpeläinenMLindqvistALaitinenTIndividual FEV1 trajectories can be identified from a COPD cohortCOPD20161342543026807738
   PubMedGoogle Scholar
• DawkinsPADawkinsCLWoodAMNightingalePGStockleyJAStockleyRARate of progression of lung function impairment in alpha 1-antitrypsin deficiencyEur Respir J2009331338134419164359
   PubMed Web of Science ®Google Scholar
• McElvaneyNGStollerJKBuistASBaseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study GroupChest19971113944039041988
   PubMed Web of Science ®Google Scholar
• CrimCDransfieldMTBourbeauJPneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDAnn Am Thorac Soc201512273425490706
   PubMed Web of Science ®Google Scholar
• DransfieldMTKunisakiKMStrandMJAcute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201719532433027556408
   PubMed Web of Science ®Google Scholar
• GramegnaAAmatiFTerranovaLNeutrophil elastase in bronchiectasisRespir Res20171821129258516
   PubMed Web of Science ®Google Scholar
• StockleyRALuisettiMMiravitllesMPiitulainenEFernandezPon behalf of the Alpha One International Registry (AIR) groupOngoing research in Europe: Alpha One International Registry (AIR) objectives and developmentEur Respir J20072958258617329492
   PubMed Web of Science ®Google Scholar
• NishimuraMMakitaHNagaiKAnnual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012185445222016444
   PubMed Web of Science ®Google Scholar
• BurrowsBBloomJWTraverGAClineMGThe course and prognosis of different forms of chronic airways obstruction in a sample from the general populationN Engl J Med1987317130913143683459
   PubMed Web of Science ®Google Scholar
• TanashHAEkströmMRönmarkELindbergAPiitulainenESurvival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habitsEur Respir J201750170019828889108
   PubMed Web of Science ®Google Scholar
• SeersholmNWenckerMBanikNDoes alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary AAT deficiency? WATL alpha-1 study groupEur Respir J199710226022639387950
   PubMed Web of Science ®Google Scholar
• StockleyRAParrDGPiitulainenEStolkJStoelBCDirksenATherapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometryRespir Res20101113620920370
   PubMed Web of Science ®Google Scholar
• ChapmanKRBurdonJGPiitulainenEIntravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialLancet201538636036826026936
   PubMed Web of Science ®Google Scholar
• StockleyRAMiravitllesMVogelmeierCAugmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet J Rare Dis2013814924063809
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEKileyJPEffects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health StudyJAMA1994272149715057966841
   PubMed Web of Science ®Google Scholar
• DirksenAPiitulainenEParrDGExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J2009331345135319196813
   PubMed Web of Science ®Google Scholar
• EsquinasCJanciauskieneSGonzaloRGene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema with PiZZ alpha1-antitrypsin deficiencyInt J Chron Obst Pulmon Dis20171233813390
   PubMed Web of Science ®Google Scholar